Intec Parent (Intec Parent) Research & Development : $6.87 Mil (TTM As of Mar. 2021)

View and export this data going back to 1996. Start your Free Trial

What is Intec Parent Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Intec Parent's Research & Development for the three months ended in Mar. 2021 was $2.16 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2021 was $6.87 Mil.

Intec Parent Research & Development Historical Data

The historical data trend for Intec Parent's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Research & Development Chart

Intec Parent Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Research & Development

Get a 7-Day Free Trial

10.75

24.30

35.40

26.66

6.74

Intec Parent Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Research & Development	Get a 7-Day Free Trial															2.02	1.28	2.11	1.33	2.16

Intec Parent Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.87 Mil.

Intec Parent (NAS:NTEC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Intec Parent Research & Development Related Terms

Thank you for viewing the detailed overview of Intec Parent's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Intec Parent (Intec Parent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Parent Inc (NAS:NTEC) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512

Website

https://www.intecpharma.com

Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.

Executives

Walt Addison Linscott	officer: Chief Business Officer	1860 MONTREAL ROAD, TUCKER GA 30084
Nir Sassi	officer: Chief Financial Officer	3 ELUL STREET, APT. 6, MODIIN L3 7176397
Nadav Navon	officer: Chief Operating Officer	18 LEA IMENU STREET MODIIN L3 7177945
Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes	director	231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah	director	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
John W Kozarich	director	10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Jeffrey A Meckler	director, officer: Chief Executive Officer	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
R Michael Gendreau	officer: Chief Medical Officer	4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Gil Bianco	director	7 HAORANIM STREET BAZRA L3 60944